KR102219919B1 - 히드로코티손을 포함하는 조성물 - Google Patents

히드로코티손을 포함하는 조성물 Download PDF

Info

Publication number
KR102219919B1
KR102219919B1 KR1020157035705A KR20157035705A KR102219919B1 KR 102219919 B1 KR102219919 B1 KR 102219919B1 KR 1020157035705 A KR1020157035705 A KR 1020157035705A KR 20157035705 A KR20157035705 A KR 20157035705A KR 102219919 B1 KR102219919 B1 KR 102219919B1
Authority
KR
South Korea
Prior art keywords
composition
hydrocortisone
hydroxypropylmethylcellulose
layer
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157035705A
Other languages
English (en)
Korean (ko)
Other versions
KR20160011205A (ko
Inventor
히엡 화탄
리차드 로스
마틴 휘터커
노베르트 포엘링거
아네트 그레이브
Original Assignee
다이어널 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이어널 리미티드 filed Critical 다이어널 리미티드
Publication of KR20160011205A publication Critical patent/KR20160011205A/ko
Application granted granted Critical
Publication of KR102219919B1 publication Critical patent/KR102219919B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020157035705A 2013-05-17 2014-05-12 히드로코티손을 포함하는 조성물 Active KR102219919B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1308933.9 2013-05-17
GBGB1308933.9A GB201308933D0 (en) 2013-05-17 2013-05-17 Paediatric composition
PCT/GB2014/051442 WO2014184525A1 (en) 2013-05-17 2014-05-12 Composition comprising hydrocortisone

Publications (2)

Publication Number Publication Date
KR20160011205A KR20160011205A (ko) 2016-01-29
KR102219919B1 true KR102219919B1 (ko) 2021-02-25

Family

ID=48746932

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157035705A Active KR102219919B1 (ko) 2013-05-17 2014-05-12 히드로코티손을 포함하는 조성물

Country Status (25)

Country Link
US (1) US9649280B2 (https=)
EP (1) EP2978414B1 (https=)
JP (1) JP6371379B2 (https=)
KR (1) KR102219919B1 (https=)
CN (1) CN105120848B (https=)
AU (1) AU2014267041B2 (https=)
BR (1) BR112015028025B1 (https=)
CA (1) CA2909060C (https=)
CY (1) CY1123284T1 (https=)
DK (1) DK2978414T3 (https=)
ES (1) ES2813382T3 (https=)
GB (2) GB201308933D0 (https=)
HR (1) HRP20201315T1 (https=)
HU (1) HUE050917T2 (https=)
IL (1) IL242275B (https=)
LT (1) LT2978414T (https=)
MX (1) MX379168B (https=)
PL (1) PL2978414T3 (https=)
PT (1) PT2978414T (https=)
RS (1) RS60734B1 (https=)
RU (1) RU2664678C2 (https=)
SI (1) SI2978414T1 (https=)
SM (1) SMT202000473T1 (https=)
WO (1) WO2014184525A1 (https=)
ZA (1) ZA201507210B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201119985D0 (en) 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
GB201308933D0 (en) 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition
US20190180872A1 (en) * 2017-12-12 2019-06-13 International Business Machines Corporation Second Opinion Decision Support Using Patient Electronic Medical Records
WO2025144994A1 (en) * 2023-12-29 2025-07-03 Regents Of The University Of Minnesota Compositions and methods for intranasal delivery of hydrocortisone
WO2025240605A1 (en) 2024-05-15 2025-11-20 Neurocrine Biosciences, Inc. Combination treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287211A1 (en) * 2004-04-30 2005-12-29 Astellas Pharma Inc. Oral pharmaceutical compositions in timed-release particle form and fast-disintegrating tablets containing this composition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2050067C (en) 1990-08-30 2000-05-30 Yasushi Morita Controlled drug release composition
KR19990077278A (ko) 1996-01-16 1999-10-25 마이클 오코넬 약물의 하부 위장관으로의 국소적 전달
KR20040016202A (ko) * 2002-08-16 2004-02-21 주식회사 제이알팜 쓴맛이 차폐된 히드로코르티손 경구용 약제 조성물 및 그제조방법
SE0401031D0 (sv) 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
EP1744760B1 (en) 2004-04-22 2015-01-07 AcuCort AB Pharmaceutical compositions for acute glucocorticoid therapy
ATE474601T1 (de) * 2004-05-31 2010-08-15 Almirall Sa Kombinationen mit antimuskarin-wirkstoffen und pde4-hemmern
US20070281007A1 (en) * 2004-08-27 2007-12-06 Jacob Jules S Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs
RU2290940C2 (ru) * 2004-10-18 2007-01-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская Государственная Медицинская академия" МЗ РФ (ГОУ ВПО НижГМА) Средство для коррекции острой почечной недостаточности при токсическом гепаторенальном синдроме, индуцированном четыреххлористым углеродом, и способ коррекции острой почечной недостаточности при токсическом гепаторенальном синдроме, индуцированном четыреххлористым углеродом
BRPI0611075A2 (pt) * 2005-06-03 2010-08-03 Elan Pharma Int Ltd formulações de acetaminofeno em nanopartìcula
EP2120868A4 (en) * 2007-04-11 2010-08-25 Perrigo Israel Phamaceuticals LOW-DOSED MOMETASON FORMULATIONS
GB0817120D0 (en) 2008-09-19 2008-10-29 Diurnal Ltd Treatment of adrenal insufficiency
WO2010115615A1 (en) 2009-04-07 2010-10-14 Duocort Pharma Ab Improved glucocorticoid therapy
NZ624922A (en) * 2009-10-01 2016-05-27 Adare Pharmaceuticals Inc Orally administered corticosteroid compositions
AU2010325746B2 (en) * 2009-12-02 2016-02-25 Adare Pharmaceuticals S.R.L. Fexofenadine microcapsules and compositions containing them
AU2011254959A1 (en) 2010-05-20 2013-01-10 Duocort Pharma Ab Posology and administration of glucocorticoid based compositions
GB201119985D0 (en) * 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
GB201308933D0 (en) 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287211A1 (en) * 2004-04-30 2005-12-29 Astellas Pharma Inc. Oral pharmaceutical compositions in timed-release particle form and fast-disintegrating tablets containing this composition

Also Published As

Publication number Publication date
BR112015028025A8 (pt) 2019-12-31
CY1123284T1 (el) 2021-12-31
GB201516973D0 (en) 2015-11-11
LT2978414T (lt) 2020-09-25
MX2015015759A (es) 2016-03-15
RU2664678C2 (ru) 2018-08-21
JP6371379B2 (ja) 2018-08-08
JP2016518439A (ja) 2016-06-23
ZA201507210B (en) 2017-07-26
IL242275B (en) 2018-08-30
MX379168B (es) 2025-03-10
ES2813382T3 (es) 2021-03-23
NZ712756A (en) 2020-12-18
CN105120848B (zh) 2019-06-04
EP2978414B1 (en) 2020-07-22
RU2015150303A3 (https=) 2018-03-26
CA2909060C (en) 2020-03-10
EP2978414A1 (en) 2016-02-03
AU2014267041B2 (en) 2018-11-22
HK1214131A1 (zh) 2016-07-22
SI2978414T1 (sl) 2020-10-30
HRP20201315T1 (hr) 2020-11-27
HUE050917T2 (hu) 2021-01-28
PT2978414T (pt) 2020-08-27
WO2014184525A1 (en) 2014-11-20
US20160081942A1 (en) 2016-03-24
PL2978414T3 (pl) 2020-11-16
RU2015150303A (ru) 2017-06-22
BR112015028025B1 (pt) 2022-11-29
DK2978414T3 (da) 2020-08-24
GB2527233A (en) 2015-12-16
RS60734B1 (sr) 2020-09-30
KR20160011205A (ko) 2016-01-29
CN105120848A (zh) 2015-12-02
GB201308933D0 (en) 2013-07-03
US9649280B2 (en) 2017-05-16
GB2527233B (en) 2017-07-05
SMT202000473T1 (it) 2020-11-10
CA2909060A1 (en) 2014-11-20
AU2014267041A1 (en) 2015-10-15
BR112015028025A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
KR102219919B1 (ko) 히드로코티손을 포함하는 조성물
US9717740B1 (en) Treatment of adrenal insufficiency
KR20180069907A (ko) 리시노프릴 제제
US20220323429A1 (en) Pimavanserin for treating neurodegenerative diseases
RU2619869C2 (ru) Композиция гидрокортизона с контролируемым высвобождением
US20190133977A1 (en) Delayed release oral tamsulosin hydrochloride
NZ712756B2 (en) Composition comprising hydrocortisone
EP2558079B1 (en) Ciprofloxacin dry syrup composition
Rooman Compounded hydrocortisone preparations for children with congenital adrenal hyperplasia: are they safe?
TW200840590A (en) Compositions and methods for prevention and treatment of cachexia

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6